<DOC>
	<DOCNO>NCT03023878</DOCNO>
	<brief_summary>A phase 2 , multicenter , open-label , single arm clinical trial adult subject newly diagnose aggressive high-risk DLBCL .</brief_summary>
	<brief_title>Safety Efficacy Blinatumomab Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>The safety profile blinatumomab frontline R-chemotherapy , consist either R-CHOP ( 14 21 ) R-DA-EPOCH/R-CHOEP , determine . The study consist screen period 14 day , standard care ( SOC ) R-chemotherapy run-in period approximately 21 week , 12 16 week blinatumomab treatment period , 30-day safety follow-up visit , long-term follow-up period begin safety follow-up visit complete 1 year first dose blinatumomab .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Inclusion criterion : Subject provide informed consent prior initiation studyspecific activities/procedures Age ≥ 18 time inform consent Subject must untreated , histologically proven highrisk DLBCL define IPI 3 5 and/or Doublehit double protein expression Eastern Cooperative Oncology Group performance status ≤ 2 . Subject meet criteria per investigator 's institution receive SOC Rchemotherapy ( ie , RCHOP [ 14 21 ] RDAEPOCH/RCHOEP ) 6 cycle . Subjects may enrol study prior cycle 1 cycle 2 Adequate organ function determine within 14 day prior enrollment define : Hematological : Absolute neutrophil count ≥1x10^9/L ; platelet count ≥75x10^9/L ; Renal : creatinine clearance ≥50mL/min ; Hepatic : Aspartate aminotransferase/Alanine aminotransferase &lt; 3X upper limit normal ( ULN ) ; Total bilirubin &lt; 2X ULN ( unless Gilbert 's Disease liver involvement lymphoma ) Subject must complete 6 cycle Rchemotherapy achieve CR , PR stable disease PET/CT perform 3 week ( ± 3 day ) cycle 6 SOC Rchemotherapy . Subjects PD eligible treatment blinatumomab end study . Clinically relevant central nervous system pathology require treatment epilepsy , seizure , paresis , aphasia , stroke , severe brain injury , dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , psychosis Evidence CNS involvement NHL Current autoimmune disease history autoimmune disease potential CNS involvement Subject active infection require systemic therapy Prior antiCD19 therapy Known infection HIV chronic infection hepatitis B virus hepatitis C virus History malignancy within past 3 year follow exception : Malignancy treat curative intent know active disease present ≥ 3 year enrollment felt low risk recurrence treat physician Adequately treated nonmelanoma skin cancer lentigo malignancy without evidence disease Adequately treat cervical carcinoma situ without evidence disease Adequately treat breast ductal carcinoma situ without evidence disease Prostatic intraepithelial neoplasia without evidence prostate cancer Adequately treat urothelial papillary noninvasive carcinoma carcinoma situ Subject know hypersensitivity immunoglobulins product component administer dose . Subject likely available complete protocolrequired study visit procedure , and/or comply require study procedure best subject 's investigator 's knowledge . History/evidence clinically significant disorder , condition disease ( exception outline ) , opinion investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedures completion . Females pregnant breastfeeding planning become pregnant breastfeed receive blinatumomab additional 48 hour last treatment dose blinatumomab . Currently receive treatment another investigational device drug study le 30 day since end treatment another investigational device drug study . Other investigational procedure participate study exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>